Use of emerging testing technologies and approaches for SARS-CoV-2: review of literature and global experience in an Australian context.
Use of emerging testing technologies and approaches for SARS-CoV-2: review of literature and global experience in an Australian context.
复制标题
DOI：
10.1016/j.pathol.2021.08.001
复制
发表时间：
2021-10
期刊：
影响因子：
4.5
通讯作者：
Howden BP
中科院分区：
文献类型：
--
作者：
Graham M;Ballard SA;Pasricha S;Lin B;Hoang T;Stinear T;Druce J;Catton M;Sherry N;Williamson D;Howden BP
用于检测SARS-CoV-2的新兴检测技术包括那些快速且可用于护理点（POC）的技术，以及那些促进高通量实验室检测的技术。设计用于在POC进行的检测（如抗原检测和分子检测）有可能加快对感染性患者及其接触者的隔离，但大多数检测的灵敏度低于标准逆转录聚合酶链反应（RT-PCR）。大多数新兴检测试剂盒的临床性能数据有限，大多数评价是对人工或储存的实验室样本进行的。需要对这些检测进行进一步评价，特别是在POC对有症状和无症状患者以及在症状发作后的不同时间点进行检测时。到目前为止，一些研究表明这些检测中的几种具有高特异性。然而，需要进行大规模的前瞻性评价来确认特异性，特别是在低患病率环境或无症状人群中实施检测之前。基于实验室的高通量测试包括使用新的样品类型（例如，唾液以增加可接受性）或现有技术的创新使用（例如，样品合并）。同行评审文献中大部分缺少详细说明SARS-COV-2人群范围检测策略的信息。物流和供应链是在澳大利亚范围内“扩大”测试计划的关键考虑因素。战略性地使用新的检测方法将有助于在实现足够的检测数量而不需要压倒性的实验室能力之间取得平衡。为了保护对高危人群的检测，必须考虑检测的目的与大流行的阶段有关。
Emerging testing technologies for detection of SARS-CoV-2 include those that are rapid and can be used at point-of-care (POC), and those facilitating high throughput laboratory-based testing. Tests designed to be performed at POC (such as antigen tests and molecular assays) have the potential to expedite isolation of infectious patients and their contacts, but most are less sensitive than standard-of-care reverse transcription polymerase chain reaction (RT-PCR). Data on clinical performance of the majority of emerging assays are limited with most evaluations performed on contrived or stored laboratory samples. Further evaluations of these assays are required, particularly when performed at POC on symptomatic and asymptomatic patients and at various time-points after symptom onset. A few studies have so far shown several of these assays have high specificity. However, large prospective evaluations are needed to confirm specificity, particularly before the assays are implemented in low prevalence settings or asymptomatic populations. High throughput laboratory-based testing includes the use of new sample types (e.g., saliva to increase acceptability) or innovative uses of existing technology (e.g., sample pooling). Information detailing population-wide testing strategies for SARS-COV-2 is largely missing from peer-reviewed literature. Logistics and supply chains are key considerations in any plan to ‘scale up’ testing in the Australian context. The strategic use of novel assays will help strike the balance between achieving adequate test numbers without overwhelming laboratory capacity. To protect testing of high-risk populations, the aims of testing with respect to the phase of the pandemic must be considered.
登录
查看更多内容
DOI：
10.1016/j.jinf.2021.02.014
发表时间：
2021-03
期刊：
The Journal of infection
影响因子：
--
作者：
Bulilete O;Lorente P;Leiva A;Carandell E;Oliver A;Rojo E;Pericas P;Llobera J;COVID-19 Primary Care Research Group
通讯作者：
COVID-19 Primary Care Research Group
影响因子：
3.9
作者：
Czumbel, Laszlo Mark;Kiss, Szabolcs;Varga, Gabor
通讯作者：
Varga, Gabor
影响因子：
4.5
作者：
Chong BSW;Tran T;Druce J;Ballard SA;Simpson JA;Catton M
通讯作者：
Catton M
影响因子：
4.8
作者：
Chaimayo C;Kaewnaphan B;Tanlieng N;Athipanyasilp N;Sirijatuphat R;Chayakulkeeree M;Angkasekwinai N;Sutthent R;Puangpunngam N;Tharmviboonsri T;Pongraweewan O;Chuthapisith S;Sirivatanauksorn Y;Kantakamalakul W;Horthongkham N
通讯作者：
Horthongkham N
影响因子：
3.5
作者：
Edson, Daniel C.;Casey, Danielle L.;Downes, Frances P.
通讯作者：
Downes, Frances P.